Daily Stock Opinions and Ratings

Opinions

Jim Cramer - Mad MoneyAlign Technology IncALGNBUYFeb 08, 2023

Down 67% last year, a pandemic victim. It turned around in Q4 by offering stability that shareholders applauded. Was the 3rd-worst performer in 2022, but is the 2nd-best performer in 2023.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$334.36

Stock price when the opinion was issued

$174.84

As of Jun 12, 2026. Market Open.

Telecommunications

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

Wealthica Track your Stocks in your Watch List

You might be interested:

STRONG BUY

Was upgraded today. This was a huge pandemic winner, peaking at $730. Shares are up 70% this year to $373. She bought it way down, nearly doubling her hold in worth. The braces market is huge for teenagers as well as adults. She has recommended this before and still does.

BUY

Had a great move to start the year, has been building a base, and people are starting to spend money on goods. Great product.

PARTIAL BUY

#5 stock in Q1, up 58%. Pre-Covid, it was a great growth stocks, but slid after Covid. Is recovering now though selling at a rich 40x PE. If Wall Street doesn't shun growth stocks again, this can rise higher.

BUY

Shares have fallen $700 to $200. China is a big growth market for them, and China will reopen and grow. Traeds at 25x PE. 20% 5-year growth rate. Dominates this industry.

SELL ON STRENGTH

Oil was up so huge, then gave back those gains. As ALGN goes back up, trim some. Take some profits in oil and let the rest run.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick May 06/21, Up 0.95%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ALGN has triggered its stop at $590. To remain disciplined, we recommend covering the balance of the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment return over 10%.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick May 06/21, Up 20.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ALGN has achieved its target of $707. To remain disciplined, we recommend covering 50% of the position and trailing up the stop (from $400) to $590.

DON'T BUY

Not interested, based on valuation. Trading at 10-11x revenue. Good news already built in. Good technology, good company, but he'd pass.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly During the pandemic, orthodontic services have been restricted. ALGN allows patients a safe, lower cost way, to achieve their goal for a better dental appearance. Patients work with orthodontists, but wear an aligner for their teeth that is not visible to others. Management just amped up their sales expectations to $3.7-$3.9 billion for the year, compared to analyst expectations of $3.49 billion. The company is expanding to include Europe, Japan and China. The company continues to build cash reserves, now estimated over $1.2 billion. We would buy this with a stop loss at $400, looking to achieve $707 -- upside potential over 25%. Yield 0% (Analysts’ price target is $707.00)

COMMENT

Fractional shares to buy instead of playing the short squeeze of GameStop, AMC, etc. They make Invisiline. They have a lot going for it. Your teeth are always on display when you Zoom or appear on Instagram.

DON'T BUY

This falls into the medical device category, which he likes. The stock has gone parabolic and earnings beats have been great. It has a 50+ PE ratio. It will have to grow into that ratio before he would be buyer – needing at least 50% earnings growth.

COMMENT

His investment team has been debating this for a year. He really likes the company. This has technology for braces for teeth, that is non-invasive, easy to apply, and you don’t have to be an orthodontist to apply the technology. They are growing very rapidly globally. It has a very large addressable market. It appeals to mature individuals as it doesn’t show up in your mouth. He likes this one and wishes he was a shareholder.

Most Recent Experts